Displaying drugs 7576 - 7600 of 8274 in total
Snubh-nm-333 F-18
Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).
Investigational
Matched Description: … -333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of …
Dihydromyricetin
Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).
Investigational
Matched Description: … Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on …
FF-10101-01
FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Description: … FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With …
PT-2385
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Description: … PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau …
Darovasertib
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Investigational
Matched Description: … IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid …
Avotaciclib
Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).
Investigational
Matched Description: … Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in …
NDX-3315
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of …
Abiraterone decanoate
Abiraterone decanoate is under investigation in clinical trial NCT04729114 (Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer).
Investigational
Matched Description: … Abiraterone decanoate is under investigation in clinical trial NCT04729114 (Open-label, Multicenter Study of …
Nelonicline
Nelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).
Investigational
Matched Description: … investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of …
NN344
NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … The product is intended for basal insulin treatment of diabetes mellitus. …
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
PI-166
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, …
IRL-1620
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
Matched Description: … models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of …
Muplestim
Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia).
Investigational
Matched Description: … trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of …
Azintuxizumab vedotin
Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment).
Investigational
Matched Description: … Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and …
TMC-649128
TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin).
Investigational
Matched Description: … Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of …
Amlitelimab
Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)).
Investigational
Matched Description: … Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of …
CYT006-AngQb
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Allogeneic Cardiosphere-Derived Cells
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
Droloxifene
Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell...
Investigational
Matched Description: … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor ... affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of ... Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because …
Ohmefentanyl
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which...
Illicit
Matched Description: … Researchers are studying the different pharmaceutical properties of these isomers. ... Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids …
LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications...
Investigational
Matched Description: … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered ... For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of …
Vanillic acid
A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).
Experimental
Matched Description: … It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. …
Displaying drugs 7576 - 7600 of 8274 in total